Skip to content
drillr.ai

KOD

Kodiak Sciences Inc.

NASDAQ · USHealthcareBiotechnology
$40.87-4.15%

Price as of Jul 20, 2026

KOD news

Kodiak Sciences Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

    Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference PR Newswire PALO ALTO, Calif., May 28, 2026 PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday

    PR Newswire ·

  2. Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

    Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences PR Newswire PALO ALTO, Calif., May 1, 2026 * Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK

    PR Newswire ·

  3. Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results PR Newswire PALO ALTO, Calif., March 31, 2026 PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancin

    PR Newswire ·

  4. Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

    Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham PR Newswire PALO ALTO, Calif., March 26, 2026 * Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compar

    PR Newswire ·